Asparaginase erythrocyte encapsulated - ERYtech Pharma

Drug Profile

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase; GRASPA; L-asparaginase loaded erythrocytes

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ERYtech Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Acute lymphoblastic leukaemia
  • Phase II Acute myeloid leukaemia; Pancreatic cancer
  • Preclinical Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 10 Oct 2017 Preregistration for Acute lymphoblastic leukaemia (In adolescents, In children, In infants, In adults) in European Union (IV)
  • 11 Sep 2017 ERYtech Pharma intends to meet with the US FDA on further Acute lymphoblastic leukaemia development plan over next 12 months (by September 2018)
  • 11 Sep 2017 ERYtech Pharma intends to meet with FDA and CHMP to discuss next steps for development of asparaginase erythrocyte encapsulated in Pancreatic cancer before the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top